Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 556

Results For "NAL"

5924 News Found

Union Minister Mansukh Mandaviya chairs meet on eradicating TB
Policy | September 02, 2021

Union Minister Mansukh Mandaviya chairs meet on eradicating TB

Coordinated and collaborative efforts will strongly contribute to the achievement of shared goals faster: Mandaviya


Pharma tops India’s exports from SEZs
News | September 01, 2021

Pharma tops India’s exports from SEZs

As of June 30, 2021, 267 out of a total of 427 SEZs approved by the government are operational


Abbott launch room-temperature carbetocin in India for Postpartum Haemorrhage
News | September 01, 2021

Abbott launch room-temperature carbetocin in India for Postpartum Haemorrhage

PPH is associated with almost 20 per cent of maternal mortality in India


Ami Organics bets on strategic acquisitions as its IPO opens on Sept 1
News | September 01, 2021

Ami Organics bets on strategic acquisitions as its IPO opens on Sept 1

The company aims to continue its expansion via organic and inorganic routes to increase production capacity and product portfolio


WHO releases compendium of innovative health technologies
Policy | September 01, 2021

WHO releases compendium of innovative health technologies

The Covid-19 pandemic has exposed the divide that exists between rich and developing nations and to address these challenges the World Health Organisation (WHO), has compiled a list of innovative health technologies that aim to bridge the gap


Zymo Research receives CE Mark for new Covid-19 SafeCollect kits
Drug Approval | September 01, 2021

Zymo Research receives CE Mark for new Covid-19 SafeCollect kits

Self-collection devices designed for ease of use and safety


Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab
Drug Approval | September 01, 2021

Positive results from Pfizer’s Phase 3 trail comparing efficacy of abrocitinib and dupilumab

JADE DARE trial met co-primary and key secondary endpoints and demonstrated a safety profile consistent with previous studies for moderate to severe atopic dermatitis


US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723
Drug Approval | August 31, 2021

US FDA clears InnoCare’s clinical trial of pan-TRK Inhibitor ICP-723

The clinical trial will evaluate the safety, tolerability and pharmacokinetic properties of ICP-723 in patients with solid tumours, and evaluate the anti-tumour efficacy of ICP-723 on NTRK fusion-positive cancers


Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis
Biotech | August 31, 2021

Sanofi’s Dupixent pivotal trial meets all primary and secondary endpoints for treatment of atopic dermatitis

Results reinforce the well-established safety profile of Dupixent - the first-ever biologic medicine for atopic dermatitis currently approved for patients as young 6 years old


Vivo Bio Tech enters long-term contract with Bio E
Biotech | August 30, 2021

Vivo Bio Tech enters long-term contract with Bio E

The value of the contract is estimated to be between Rs 20-30 crores per year for the next three years